A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer.
Saved in:
| Title: | A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer. |
|---|---|
| Authors: | Noguchi E; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Yamanaka T; Department of Breast Surgery and Oncology, Kanagawa Cancer Center, Yokohama, Japan., Mukai H; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Yamamoto N; Department of Breast Surgery, Chiba Cancer Center Hospital, Chiba, Japan., Chung CF; Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan., Lu YS; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Chang DY; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Sohn J; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea., Kim GM; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea., Lee KH; Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University, Seoul, Republic of Korea., Lee SC; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore., Iwasa T; Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka, Japan., Iwata H; Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan., Watanabe K; Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan., Jung KH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Tanabe Y; Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan., Kang SY; Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Republic of Korea., Yasojima H; Departments of Surgery and Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan., Aogi K; Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan., Tokunaga E; Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan., Sim SH; Center for Breast Cancer, National Cancer Center, Goyang-Si, Republic of Korea., Yap YS; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore., Matsumoto K; Hyogo Cancer Center Division of Medical Oncology, Akashi, Japan., Tseng LM; Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan., Umeyama Y; Pfizer R&D Japan, Tokyo, Japan., Sudo K; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Kojima Y; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Hata T; International Trial Management Section, Research Management Division, Clinical Research Support Office, National Cancer Center Hospital, Tokyo, Japan., Kuchiba A; Biostatistics Section, Clinical Research Support Office National Cancer Center Hospital/Biostatistics Division, Center for Research Administration and Support, National Cancer Center, Tokyo, Japan., Shibata T; Biostatistics Section, Clinical Research Support Office National Cancer Center Hospital/Biostatistics Division, Center for Research Administration and Support, National Cancer Center, Tokyo, Japan., Nakamura K; Department of International Clinical Development, National Cancer Center Hospital, Tokyo, Japan., Fujiwara Y; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Tamura K; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Yonemori K; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. kyonemor@ncc.go.jp. |
| Source: | NPJ breast cancer [NPJ Breast Cancer] 2024 Aug 22; Vol. 10 (1), pp. 76. Date of Electronic Publication: 2024 Aug 22. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2374-4677 |
|---|---|
| DOI: | 10.1038/s41523-024-00684-w |
